Christopher C Verni1, Antonio Davila, Steve Balian, Carrie A Sims, Scott L Diamond. 1. From the Department of Chemical and Biomolecular Engineering (C.C.V., S.L.D.), Institute for Medicine and Engineering, University of Pennsylvania; Penn Acute Research Collaboration (PARC) (A.D., S.B., C.A.S.), and Department of Trauma Surgery (C.A.S.), Penn Presbyterian Medical Center, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Trauma-induced coagulopathy occurs in about 25% of injured patients and accounts for about 10% of deaths worldwide. Upon injury, hemostatic function may decline due to vascular dysfunction, clotting factor deficiencies, hyperfibrinolysis, and/or platelet dysfunction. We investigated agonist-induced calcium signaling in platelets obtained over time from trauma patients. METHODS: Platelets from trauma patients and healthy donors were monitored via intracellular calcium mobilization and flow cytometry markers (α2bβ3 activation, P-selectin display, and phosphatidylserine exposure) following stimulation with a panel of agonists (adenosine 5'-diphosphate sodium salt, U46619, convulxin, PAR-1/4 activating peptides, iloprost) used in isolation or in pairwise tests. Furthermore, healthy donor platelets were tested in heterologous plasma isolated from healthy subjects and trauma patients. RESULTS: When exposed to agonists over the first 24 hours postinjury, trauma patient platelets mobilized less calcium in comparison to healthy platelets. Partial recovery of platelet activity was observed in about a third of patients after 120 hours, although not fully obtaining healthy baseline function. Flow cytometry markers of trauma platelets were similar to healthy platelets prior to stimulation, but were depressed in trauma platelets stimulated with adenosine 5'-diphosphate sodium salt or convulxin. Also, washed healthy platelets showed a significant reduction in calcium mobilization when reconstituted in plasma from trauma patients, relative to healthy plasma, at all plasma doses tested. CONCLUSION: Platelet dysfunction in trauma patients included poor response to multiple agonists relevant to hemostatic function. Furthermore, the inhibitor effect of patient plasma on healthy platelets suggests that soluble plasma species may downregulate endogenous or transfused platelets during trauma.
BACKGROUND:Trauma-induced coagulopathy occurs in about 25% of injured patients and accounts for about 10% of deaths worldwide. Upon injury, hemostatic function may decline due to vascular dysfunction, clotting factor deficiencies, hyperfibrinolysis, and/or platelet dysfunction. We investigated agonist-induced calcium signaling in platelets obtained over time from traumapatients. METHODS: Platelets from traumapatients and healthy donors were monitored via intracellular calcium mobilization and flow cytometry markers (α2bβ3 activation, P-selectin display, and phosphatidylserine exposure) following stimulation with a panel of agonists (adenosine 5'-diphosphate sodium salt, U46619, convulxin, PAR-1/4 activating peptides, iloprost) used in isolation or in pairwise tests. Furthermore, healthy donor platelets were tested in heterologous plasma isolated from healthy subjects and traumapatients. RESULTS: When exposed to agonists over the first 24 hours postinjury, traumapatient platelets mobilized less calcium in comparison to healthy platelets. Partial recovery of platelet activity was observed in about a third of patients after 120 hours, although not fully obtaining healthy baseline function. Flow cytometry markers of trauma platelets were similar to healthy platelets prior to stimulation, but were depressed in trauma platelets stimulated with adenosine 5'-diphosphate sodium salt or convulxin. Also, washed healthy platelets showed a significant reduction in calcium mobilization when reconstituted in plasma from traumapatients, relative to healthy plasma, at all plasma doses tested. CONCLUSION:Platelet dysfunction in traumapatients included poor response to multiple agonists relevant to hemostatic function. Furthermore, the inhibitor effect of patient plasma on healthy platelets suggests that soluble plasma species may downregulate endogenous or transfused platelets during trauma.
Authors: Markus Bender; Sebastian Hofmann; David Stegner; Athena Chalaris; Michael Bösl; Attila Braun; Jürgen Scheller; Stefan Rose-John; Bernhard Nieswandt Journal: Blood Date: 2010-07-19 Impact factor: 22.113
Authors: John R Hess; Karim Brohi; Richard P Dutton; Carl J Hauser; John B Holcomb; Yoram Kluger; Kevin Mackway-Jones; Michael J Parr; Sandro B Rizoli; Tetsuo Yukioka; David B Hoyt; Bertil Bouillon Journal: J Trauma Date: 2008-10
Authors: Paul Vulliamy; Samantha J Montague; Scarlett Gillespie; Melissa V Chan; Lucy A Coupland; Robert K Andrews; Timothy D Warner; Elizabeth E Gardiner; Karim Brohi; Paul C Armstrong Journal: Blood Adv Date: 2020-06-23
Authors: Jacob B Schriner; Mitchell J George; Jessica C Cardenas; Scott D Olson; Kimberly A Mankiewicz; Charles S Cox; Brijesh S Gill; Charles E Wade Journal: Shock Date: 2022-07-19 Impact factor: 3.533
Authors: Zachary A Matthay; Alexander T Fields; Brenda Nunez-Garcia; Maya H Patel; Mitchell J Cohen; Rachael A Callcut; Lucy Z Kornblith Journal: J Trauma Acute Care Surg Date: 2020-11 Impact factor: 3.313
Authors: Paul Vulliamy; Lucy Z Kornblith; Matthew E Kutcher; Mitchell J Cohen; Karim Brohi; Matthew D Neal Journal: Platelets Date: 2020-01-27 Impact factor: 3.862
Authors: Alexander Fletcher-Sandersjöö; Eric Peter Thelin; Marc Maegele; Mikael Svensson; Bo-Michael Bellander Journal: Neurocrit Care Date: 2021-04 Impact factor: 3.210
Authors: Ernest E Moore; Hunter B Moore; Lucy Z Kornblith; Matthew D Neal; Maureane Hoffman; Nicola J Mutch; Herbert Schöchl; Beverley J Hunt; Angela Sauaia Journal: Nat Rev Dis Primers Date: 2021-04-29 Impact factor: 65.038
Authors: Alexander T Fields; Zachary A Matthay; Brenda Nunez-Garcia; Ellicott C Matthay; Roland J Bainton; Rachael A Callcut; Lucy Z Kornblith Journal: Shock Date: 2021-02-01 Impact factor: 3.454